60
Participants
Start Date
September 30, 2005
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
Bevacizumab
Rituximab
Berks Hematology Oncology Associates, West Reading
Center for Cancer and Blood Disorders, Bethesda
National Capital Clinical Research Consortium, Bethesda
Spartanburg Regional Medical Center, Spartanburg
Wellstar Cancer Research, Marietta
Northeast Georgia Medical Center, Gainesville
Medical Oncology Associates of Augusta, Augusta
Integrated Community Oncology Network, Jacksonville
Florida Hospital Cancer Institute, Orlando
Watson Clinic for Cancer Research, Lakeland
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Baptist Hospital East, Louisville
Norton Cancer Institute, Louisville
Graves-Gilbert Clinic, Bowling Green
Oncology Hematology Care, Cincinnati
Providence Medical Group, Terre Haute
Methodist Cancer Center, Omaha
Hematology Oncology Clinic, LLP, Baton Rouge
Northeast Arkansas Clinic, Jonesboro
Hematology Oncology Associates of Northern NJ, Morristown
Collaborators (1)
Genentech, Inc.
INDUSTRY
SCRI Development Innovations, LLC
OTHER